Akebia Therapeutics 미래 성장

Future 기준 확인 4/6

Akebia Therapeutics은 연간 수입과 매출이 각각 59.2%와 18.5% 증가할 것으로 예상되고 EPS는 연간 60%만큼 증가할 것으로 예상됩니다.

주요 정보

59.2%

수익 성장률

60.01%

EPS 성장률

Biotechs 수익 성장	23.7%
매출 성장률	18.5%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	21 May 2025

최근 미래 성장 업데이트

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 10

Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83

Mar 16

Recent updates

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 10

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise

May 04

Vafseo And VALOR Study Will Open New Treatment Markets

Apr 28 Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%

Mar 20

Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83

Mar 16

Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified

Jan 22

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Nov 08

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Aug 02

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23

수익 및 매출 성장 예측

NasdaqCM:AKBA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	297	11	-28	-55	3
12/31/2026	291	18	-30	-57	4
12/31/2025	199	-20	35	8	4
3/31/2025	185	-45	-35	-35	N/A
12/31/2024	160	-69	-41	-41	N/A
9/30/2024	170	-46	-39	-39	N/A
6/30/2024	174	-40	-39	-39	N/A
3/31/2024	187	-43	-25	-25	N/A
12/31/2023	195	-52	-23	-23	N/A
9/30/2023	194	-59	-76	-76	N/A
6/30/2023	201	-98	-35	-35	N/A
3/31/2023	271	-58	-69	-69	N/A
12/31/2022	292	-94	-73	-73	N/A
9/30/2022	294	-158	-81	-81	N/A
6/30/2022	294	-163	-171	-171	N/A
3/31/2022	221	-276	-204	-204	N/A
12/31/2021	212	-282	-253	-253	N/A
9/30/2021	211	-299	-221	-221	N/A
6/30/2021	222	-300	-192	-192	N/A
3/31/2021	259	-392	-92	-92	N/A
12/31/2020	295	-385	-111	-110	N/A
9/30/2020	308	-391	-172	-172	N/A
6/30/2020	340	-386	-136	-134	N/A
3/31/2020	351	-268	-214	-209	N/A
12/31/2019	335	-280	-264	-257	N/A
9/30/2019	325	-245	-246	-239	N/A
6/30/2019	286	-217	-267	-262	N/A
3/31/2019	234	-193	-218	-215	N/A
12/31/2018	208	-144	N/A	-97	N/A
9/30/2018	238	-68	N/A	-40	N/A
6/30/2018	227	-65	N/A	-82	N/A
3/31/2018	206	-53	N/A	-67	N/A
12/31/2017	181	-74	N/A	-56	N/A
9/30/2017	92	-127	N/A	56	N/A
6/30/2017	51	-140	N/A	82	N/A
3/31/2017	22	-154	N/A	31	N/A
12/31/2016	2	-136	N/A	58	N/A
9/30/2016	N/A	-118	N/A	-61	N/A
6/30/2016	N/A	-101	N/A	-41	N/A
3/31/2016	N/A	-76	N/A	-27	N/A
12/31/2015	N/A	-61	N/A	-52	N/A
9/30/2015	N/A	-51	N/A	-39	N/A
6/30/2015	N/A	-41	N/A	-35	N/A
3/31/2015	N/A	-38	N/A	-30	N/A
12/31/2014	N/A	-124	N/A	-27	N/A
9/30/2014	N/A	-123	N/A	-23	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AKBA 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.9% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: AKBA (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: AKBA 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: AKBA 의 수익(연간 18.5% ) US 시장( 8.6% 보다 빠르게 성장할 것으로 예상됩니다. 8.6% 연간).

고성장 수익: AKBA 의 수익(연간 18.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AKBA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/22 09:47
장 마감 주가	2025/05/22 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Akebia Therapeutics, Inc. 21 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jonathan Aschoff	Brean Capital
Jonathan Aschoff	B. Riley Wealth
Julian Harrison	BTIG

Akebia Therapeutics 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Consensus estimates of losses per share improve by 55%

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Consensus EPS estimates upgraded to US$0.19 loss

Consensus EPS estimates upgraded to US$0.20 loss

Consensus EPS estimates fall by 38%, revenue upgraded

Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83

Recent updates

Consensus estimates of losses per share improve by 55%

Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise

Akebia Therapeutics, Inc. to Report Q1, 2025 Results on May 08, 2025

Akebia Therapeutics, Inc., Annual General Meeting, Jun 10, 2025

Vafseo And VALOR Study Will Open New Treatment Markets

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to US$0.19 loss

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANacyL, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Consensus EPS estimates upgraded to US$0.20 loss

Akebia Therapeutics, Inc. Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Akebia Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%

Consensus EPS estimates fall by 38%, revenue upgraded

Akebia Therapeutics, Inc. has filed a Follow-on Equity Offering.

Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83

New minor risk - Share price stability

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Akebia Therapeutics, Inc. to Report Q4, 2024 Results on Mar 13, 2025

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified

Akebia Therapeutics, Inc. Announces That U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo®? (vadadustat) for CKD Patients on Dialysis

Akebia Therapeutics, Inc. Announces Vadadustat Alternative Dosing Study Results

Consensus revenue estimates decrease by 12%

New major risk - Financial position

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Akebia Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Akebia Therapeutics, Inc. Announces Seven Poster Presentations at ASN Kidney Week 2024

Akebia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

New major risk - Financial position

Second quarter 2024 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2024

Akebia Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Akebia Therapeutics, Inc. Provides Update on Continued Momentum of Commercial Launch of Vafseo (Vadadustat) Tablets

Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer

Consensus estimates of losses per share improve by 14%

Consensus revenue estimates decrease by 13%

First quarter 2024 earnings released: US$0.088 loss per share (vs US$0.14 loss in 1Q 2023)

Akebia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Akebia Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Profitability

No longer forecast to breakeven

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Full year 2023 earnings: EPS exceeds analyst expectations

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Akebia Therapeutics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

CEO, President & Director recently sold US$74k worth of stock

CEO, President & Director notifies of intention to sell stock

Price target increased by 12% to US$4.33

CEO, President & Director recently sold US$78k worth of stock

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Price target increased by 29% to US$3.88

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023

Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023

Akebia Therapeutics, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Akebia Therapeutics, Inc. announced delayed 10-Q filing

Akebia Therapeutics, Inc. Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia®? (ferric Citrate) for In-Center and Home Dialysis Patients